R Rigolio
Impact in
- Geriatrics and Gerontology top 5%
- Sirtuins and Resveratrol in Medicine
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
- Oncology 19
- Cancer Treatment and Pharmacology 5
- PARP inhibition in cancer therapy 4
- Co-authors
- Guido CavalettiGabriella NicoliniG TrediciMariarosaria MilosoGiulio SanciniFrancesca ReC MeregalliL Monza
- Journals
- International Journal of Molecular Sciences (3 papers)Scientific Reports (2 papers)Molecules (2 papers)Nanomedicine Nanotechnology Biology and Medicine (2 papers)Frontiers in Immunology (1 paper)
- Partner nations
- ItalySpainUnited Kingdom
In The Last Decade
R Rigolio
39 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 104
- Geriatrics and Gerontology 70
- Biomaterials 228
- Pharmaceutical Science 93
- Neurology 102
- Structural Biology 17
Countries citing papers authored by R Rigolio
This map shows the geographic impact of R Rigolio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Rigolio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Rigolio more than expected).
Fields of papers citing papers by R Rigolio
This network shows the impact of papers produced by R Rigolio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Rigolio. The network helps show where R Rigolio may publish in the future.
Co-authorship network
The 25 scholars most cited alongside R Rigolio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2023 | 4 | |
| 3 | 2021 | 123 | |
| 4 | 2020 | 7 | |
| 5 | 2019 | 35 | |
| 6 | 2017 | 130 | |
| 7 | 2017 | 73 | |
| 8 | 2015 | 49 | |
| 9 | 2015 | 18 | |
| 10 | 2015 | 29 | |
| 11 | 2015 | 36 | |
| 12 | 2014 | 43 | |
| 13 | 2013 | 74 | |
| 14 | 2013 | 19 | |
| 15 | 2012 | 47 | |
| 16 | 2011 | 146 | |
| 17 | 2009 | 35 | |
| 18 | 2008 | 11 | |
| 19 | 2002 | 43 | |
| 20 | 2001 | 79 |
About R Rigolio
R Rigolio is a scholar working on Structural Biology, Oncology, Hematology, Applied Microbiology and Biotechnology and Neurology, having authored 39 papers that have together received 1.2k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (6 papers), Cancer Treatment and Pharmacology (5 papers), Multiple Sclerosis Research Studies (4 papers), Multiple Myeloma Research and Treatments (4 papers), Cell death mechanisms and regulation (4 papers), Systemic Lupus Erythematosus Research (4 papers), PARP inhibition in cancer therapy (4 papers) and Microtubule and mitosis dynamics (3 papers). The work is most often cited by research in Geriatrics and Gerontology (70 citations), Biomaterials (228 citations), Pharmaceutical Science (93 citations), Neurology (102 citations) and Structural Biology (17 citations). R Rigolio has collaborated with scholars based in Italy, Spain and United Kingdom. Frequent co-authors include Guido Cavaletti, Gabriella Nicolini, G Tredici, Mariarosaria Miloso, Giulio Sancini, Francesca Re, C Meregalli, L Monza, G Fumagalli and Roberta Dal Magro. Their work appears in journals such as International Journal of Molecular Sciences, Scientific Reports, Molecules, Nanomedicine Nanotechnology Biology and Medicine and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.